Bronchodilation induced by PGE<sub>2</sub> is impaired in Group III pulmonary hypertension
Gülsev Özen(Istanbul University), Xavier Norel(Inserm), Claire Danel(Assistance Publique – Hôpitaux de Paris), Adam M. Silverstein(United Therapeutics (United States)), Andrew C. Nelsen(Triangle), Dan Longrois(Hôpital Bichat-Claude-Bernard), Richard Bayles(Inserm), Lucie H. Clapp(The London College), Yves Castier(Université Claude Bernard Lyon 1), Hervé Mal(Université Claude Bernard Lyon 1), Kamel Boukais(Sorbonne Paris Cité), Salma Mani(Inserm), Chabha Benyahia(Inserm)
Cited by 14
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Comfort and patient-centred care without excessive sedation: the eCASH concept
|Intensive Care Medicine|2016|429
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Terlipressin for norepinephrine-resistant septic shock
|The Lancet|2002|259
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study
|The Lancet Respiratory Medicine|2021|254